CCDC88A Antibody

What is CCDC88A and what functional roles does it play in cellular processes?

CCDC88A, also known as Girdin, is a Galpha-interacting protein that enhances the activation of protein kinase Akt and remodels the actin cytoskeleton. It is primarily involved in the regulation of cell migration and cancer metastasis pathways . Girdin functions as a crucial signaling molecule that acts at the crossroads of G protein and Akt signaling pathways, making it particularly important in cellular motility and invasion processes. Recent research has demonstrated that Girdin interacts with other cellular proteins to coordinate cytoskeletal reorganization during cell movement, which has significant implications for both development and disease progression . Understanding the multifaceted roles of CCDC88A requires specialized antibodies that can accurately detect its expression and localization in various experimental contexts.

What applications are CCDC88A antibodies validated for?

Based on the available data, CCDC88A antibodies have been validated for multiple experimental applications including ELISA, Western Blot (WB), Immunofluorescence (IF), and Immunohistochemistry (IHC-P) . The performance characteristics may vary between different antibody preparations, with some showing better sensitivity in certain applications. For instance, the Boster Bio Anti-Girdin CCDC88A Antibody (A03282-2) has been tested specifically for ELISA, WB, and IF applications with confirmed reactivity . Meanwhile, the Sigma-Aldrich product (HPA038101) is primarily optimized for immunohistochemistry applications with recommended dilution ranges of 1:50-1:200 .

What are the recommended storage and handling protocols for CCDC88A antibodies?

For optimal antibody performance and longevity, CCDC88A antibodies should be stored according to manufacturer specifications. Typically, these antibodies can be stored at 4°C for up to three months or at -20°C for up to one year . Researchers should avoid repeated freeze-thaw cycles as this can significantly degrade antibody quality and performance. Additionally, antibodies should not be exposed to prolonged high temperatures as this may lead to denaturation and loss of specificity . Most CCDC88A antibodies are supplied in buffered solutions containing preservatives such as sodium azide (0.02%) or similar stabilizing agents, often in glycerol to prevent freezing damage .

What species reactivity do commercial CCDC88A antibodies exhibit?

Commercial CCDC88A antibodies demonstrate varying species reactivity profiles, with many products showing cross-reactivity across multiple mammalian species. The table below summarizes the species reactivity of several commercially available CCDC88A antibodies:

When selecting an antibody for cross-species applications, researchers should carefully verify the validation data supporting cross-reactivity claims and consider performing preliminary validation experiments .

What is the molecular weight discrepancy observed with CCDC88A and how does it affect antibody-based detection?

An interesting observation in CCDC88A research is the discrepancy between the calculated and observed molecular weights. According to the data from Boster Bio, while the calculated molecular weight of CCDC88A is approximately 216 kDa, the observed molecular weight in experimental settings is often around 68 kDa . This significant difference may indicate post-translational processing, alternative splicing, or degradation products. Researchers should be aware of this discrepancy when interpreting Western blot results and consider using appropriate positive controls to confirm antibody specificity. This molecular weight variation might also suggest functional differences in protein domains that could be particularly relevant for studies focused on protein-protein interactions or signaling pathway analyses involving CCDC88A.

How can researchers validate the specificity of their CCDC88A antibody?

Validating antibody specificity is crucial for generating reliable and reproducible results. For CCDC88A antibodies, researchers should consider implementing a multi-faceted validation approach:

• Positive and negative control samples: Include tissues or cell lines known to express or lack CCDC88A expression.

• Knockdown/knockout validation: Compare antibody signal in wild-type versus CCDC88A-depleted samples (siRNA, shRNA, or CRISPR-Cas9).

• Peptide blocking: Pre-incubate the antibody with the immunizing peptide to confirm signal specificity.

• Multiple antibody comparison: Use antibodies targeting different epitopes of CCDC88A to confirm consistent detection patterns.

• Mass spectrometry validation: Confirm the identity of the immunoprecipitated protein band.

Some manufacturers offer blocking peptides that can be purchased separately, which helps in determining the specificity of antibody binding. For instance, Boster Bio notes that blocking peptides are available for their Girdin antibody, with costs varying based on immunogen length .

What are the optimal conditions for using CCDC88A antibodies in immunohistochemistry?

For immunohistochemistry applications, researchers should optimize several parameters to achieve reliable and specific CCDC88A detection:

Each application may require specific optimization, and researchers should perform preliminary titration experiments to determine the optimal antibody concentration for their specific tissue samples and fixation conditions .

How does CCDC88A interact with the Akt signaling pathway and what implications does this have for cancer research?

CCDC88A/Girdin enhances the activation of protein kinase Akt, playing a critical role in cell migration and cancer metastasis . This interaction represents a significant area of interest for cancer researchers. The Girdin-Akt axis influences several cellular processes including survival, proliferation, and motility. In cancer research, understanding and targeting this interaction may provide novel therapeutic opportunities. When designing experiments to study this interaction, researchers should consider:

• Co-immunoprecipitation studies: Use CCDC88A antibodies to pull down protein complexes and assess Akt association.

• Phosphorylation analysis: Examine how CCDC88A affects Akt phosphorylation status at key residues (Ser473, Thr308).

• Functional assays: Assess cell migration, invasion, and survival in models with modulated CCDC88A expression.

• Localization studies: Use immunofluorescence to examine co-localization of CCDC88A and Akt in various subcellular compartments.

These approaches can help elucidate the mechanistic details of how CCDC88A contributes to cancer progression through Akt signaling modulation, potentially identifying new targets for therapeutic intervention.

What are the key considerations for troubleshooting non-specific binding with CCDC88A antibodies?

Non-specific binding can significantly compromise experimental results when working with CCDC88A antibodies. Researchers encountering this issue should consider the following troubleshooting approaches:

• Optimize antibody concentration: Titrate the antibody to find the optimal concentration that maximizes specific signal while minimizing background.

• Increase blocking: Use more stringent blocking conditions (higher BSA or serum concentration, longer blocking time).

• Adjust washing steps: Increase the number and duration of washes, or use more stringent washing buffers (higher salt concentration).

• Use alternative fixation methods: Different fixatives may affect epitope accessibility and non-specific binding.

• Optimize incubation conditions: Adjust temperature, time, and buffer composition for primary antibody incubation.

• Use alternative detection systems: Some secondary detection systems may provide better signal-to-noise ratios than others.

• Consider tissue-specific autofluorescence: For IF applications, use appropriate quenching methods if autofluorescence is an issue.

It's also worth noting that different lots of the same antibody may show variation in performance, so maintaining consistent sourcing is important for longitudinal studies .

What are the recommended protocols for using CCDC88A antibodies in Western blot applications?

When using CCDC88A antibodies for Western blot applications, researchers should consider the following protocol recommendations:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors

  • Include phosphatase inhibitors if studying phosphorylation status

  • Determine optimal protein loading (typically 20-50 μg total protein)

• Electrophoresis conditions:

  • Use 6-8% SDS-PAGE gels due to the large size of full-length CCDC88A (calculated MW: 216 kDa)

  • Include molecular weight markers that cover high molecular weight range

  • Consider gradient gels for better resolution of both full-length protein and potential fragments

• Transfer conditions:

  • Use wet transfer method for large proteins

  • Extend transfer time (overnight at low voltage) for efficient transfer of high molecular weight proteins

  • Verify transfer efficiency with reversible staining before blocking

• Antibody incubation:

  • Dilute primary antibody 1:500-1:2000 in appropriate blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Use validated secondary antibody with appropriate host species reactivity

• Detection and analysis:

  • Be aware of the molecular weight discrepancy (calculated: 216 kDa vs. observed: 68 kDa)

  • Consider the possibility of detecting different isoforms or processed forms of the protein

  • Include positive controls to confirm antibody specificity

Following these guidelines will help ensure reliable and reproducible detection of CCDC88A in Western blot applications.

How can researchers effectively use CCDC88A antibodies in co-immunoprecipitation studies?

Co-immunoprecipitation (Co-IP) is a valuable technique for studying protein-protein interactions involving CCDC88A. For effective Co-IP experiments with CCDC88A antibodies, researchers should consider:

• Lysis conditions optimization:

  • Use mild non-denaturing lysis buffers to preserve protein-protein interactions

  • Test different detergent concentrations (0.1-1% NP-40, Triton X-100, or CHAPS)

  • Include protease and phosphatase inhibitors to prevent degradation

• Pre-clearing step:

  • Incorporate pre-clearing with protein A/G beads to reduce non-specific binding

  • Use control IgG from the same species as the CCDC88A antibody

• Antibody selection:

  • Choose antibodies specifically validated for immunoprecipitation

  • Consider using antibodies targeting different epitopes for confirmation

  • Determine optimal antibody-to-lysate ratio through titration experiments

• Controls:

  • Include negative controls (non-specific IgG, lysates from cells lacking CCDC88A)

  • Use positive controls (known interaction partners if available)

  • Consider performing reverse Co-IP to confirm interactions

• Detection methods:

  • Western blot analysis of immunoprecipitated complexes

  • Mass spectrometry for unbiased identification of novel interaction partners

  • Consider proximity ligation assays as complementary approaches

These methodological considerations will help researchers design robust Co-IP experiments to study CCDC88A's interactome and functional relationships with other proteins.

What techniques are recommended for detecting CCDC88A localization in different subcellular compartments?

Understanding the subcellular localization of CCDC88A is crucial for elucidating its various functions. Researchers can employ several techniques to accurately determine CCDC88A distribution:

• Immunofluorescence microscopy:

  • Use CCDC88A antibodies validated for IF applications

  • Co-stain with established subcellular markers (e.g., DAPI for nucleus, phalloidin for actin cytoskeleton)

  • Employ confocal microscopy for improved resolution of subcellular structures

  • Consider super-resolution microscopy techniques for detailed localization studies

• Subcellular fractionation followed by Western blot:

  • Separate cellular components (cytosolic, membrane, nuclear, cytoskeletal fractions)

  • Analyze CCDC88A distribution across fractions by Western blot

  • Include fraction-specific markers to confirm successful fractionation

• Proximity labeling approaches:

  • Use BioID or APEX2 fusions with CCDC88A to identify proximal proteins

  • Analyze compartment-specific interactions through mass spectrometry

• Live-cell imaging:

  • Generate fluorescent protein-tagged CCDC88A constructs

  • Monitor dynamic localization changes in response to stimuli

  • Validate observations with antibody staining of endogenous protein

• Electron microscopy with immunogold labeling:

  • For ultrastructural localization studies

  • Requires antibodies specifically validated for EM applications

These approaches, used individually or in combination, can provide comprehensive insights into the dynamic localization patterns of CCDC88A under various cellular conditions and experimental treatments.

How do different fixation methods affect CCDC88A epitope recognition by antibodies?

The choice of fixation method can significantly impact CCDC88A epitope recognition by antibodies. Different fixatives modify protein structure in distinct ways, potentially masking or preserving specific epitopes:

• Paraformaldehyde/formaldehyde fixation:

  • Forms crosslinks between proteins

  • Generally preserves cytoskeletal structures (relevant for CCDC88A's cytoskeletal association)

  • May require antigen retrieval for optimal antibody binding

  • Recommended concentration: 2-4% for 10-20 minutes at room temperature

• Methanol fixation:

  • Precipitates proteins and removes lipids

  • Can improve accessibility of some epitopes while destroying others

  • Often useful for cytoskeletal proteins

  • Typically performed at -20°C for 10 minutes

• Acetone fixation:

  • Similar to methanol but sometimes less harsh

  • Can be used alone or in combination with methanol

  • Quick fixation (2-5 minutes) at cold temperatures

• Glutaraldehyde fixation:

  • Creates stronger crosslinks than formaldehyde

  • Better preserves structural details but may reduce antibody accessibility

  • Often used at low concentrations (0.1-0.5%) in combination with paraformaldehyde

Researchers should empirically determine which fixation method works best with their specific CCDC88A antibody by testing multiple fixation protocols. For immunohistochemistry applications, formalin-fixed paraffin-embedded tissues typically require heat-induced epitope retrieval methods to unmask epitopes for optimal antibody binding .

What are the implications of CCDC88A in neurological disorders and how can antibodies help investigate these connections?

Recent research suggests CCDC88A/Girdin plays important roles in neurological processes and may be implicated in various neurological disorders. From the search results, there's evidence that Girdin interacts with "Disrupted-" proteins, which likely refers to Disrupted-In-Schizophrenia 1 (DISC1), a protein associated with psychiatric disorders . This interaction suggests potential roles in neuronal development, migration, and psychiatric conditions.

To investigate these neurological connections, researchers can employ CCDC88A antibodies in several approaches:

• Comparative expression analyses:

  • Examine CCDC88A expression patterns in brain tissue from normal and disease models

  • Investigate regional and developmental expression using immunohistochemistry

  • Correlate expression levels with disease progression or severity

• Co-localization studies:

  • Determine spatial relationships between CCDC88A and neurological disease-associated proteins

  • Use dual immunofluorescence to visualize interactions in situ

  • Examine subcellular localization in neuronal cell types

• Functional studies:

  • Investigate the effects of CCDC88A knockdown/overexpression on neuronal migration

  • Assess impact on dendritic spine formation and synaptic plasticity

  • Evaluate consequences for neuronal signaling pathways

• Animal models:

  • Generate and characterize CCDC88A knockout or transgenic models

  • Assess behavioral phenotypes related to neurological function

  • Perform rescue experiments to confirm specificity

These investigative approaches using validated CCDC88A antibodies can help elucidate the protein's role in neurological disorders and potentially identify new therapeutic targets or diagnostic markers.

How can researchers quantitatively evaluate CCDC88A expression levels across different tissue samples?

Quantitative assessment of CCDC88A expression is essential for comparative studies across different tissues, disease states, or experimental conditions. Several methodological approaches can be employed:

• Western blot quantification:

  • Use validated loading controls appropriate for the tissue type

  • Employ digital image analysis software for densitometry

  • Create standard curves with recombinant protein for absolute quantification

  • Present results as fold-change relative to control samples

• Immunohistochemistry scoring systems:

  • H-score method (combines intensity and percentage of positive cells)

  • Tissue microarray analysis for high-throughput assessment

  • Digital pathology platforms for automated quantification

  • Consider both expression intensity and subcellular localization patterns

• Flow cytometry:

  • For quantification at the single-cell level

  • Requires permeabilization for intracellular CCDC88A detection

  • Can combine with other markers for subpopulation analysis

• ELISA-based quantification:

  • Develop sandwich ELISA using CCDC88A antibodies recognizing different epitopes

  • Useful for quantification in tissue lysates or biological fluids

  • Generate standard curves with recombinant CCDC88A protein

• Mass spectrometry-based approaches:

  • Absolute quantification using labeled peptide standards

  • Can distinguish between different CCDC88A isoforms or post-translational modifications

  • Requires validation with antibody-based methods

When reporting quantitative CCDC88A expression data, researchers should clearly describe the methodological approach, normalization methods, and statistical analyses employed to ensure reproducibility and comparability across studies.

What are the emerging applications of CCDC88A antibodies in cancer research and potential therapeutic development?

CCDC88A/Girdin's established role in cell migration and cancer metastasis positions it as an important target for cancer research and potential therapeutic development . Emerging applications of CCDC88A antibodies in this field include:

• Biomarker development:

  • Assessment of CCDC88A expression as a prognostic or predictive biomarker

  • Correlation of expression patterns with patient outcomes or treatment responses

  • Development of companion diagnostics for targeted therapies

• Therapeutic antibody development:

  • Generation of function-blocking antibodies targeting CCDC88A

  • Development of antibody-drug conjugates for targeted delivery to CCDC88A-expressing cells

  • Creation of bispecific antibodies linking CCDC88A recognition with immune effector recruitment

• Mechanistic investigations:

  • Elucidation of CCDC88A's role in treatment resistance mechanisms

  • Investigation of CCDC88A-mediated signaling networks in different cancer types

  • Examination of CCDC88A's contribution to tumor microenvironment interactions

• Translational research:

  • Patient-derived xenograft models to study CCDC88A function in human tumors

  • High-throughput drug screening to identify compounds modulating CCDC88A function

  • Development of CCDC88A-targeted nanoparticles for drug delivery

As research in this area continues to evolve, CCDC88A antibodies will remain essential tools for both basic science investigations and translational applications in cancer research, potentially contributing to the development of novel diagnostic approaches and therapeutic strategies.

What quality control measures should researchers implement when working with CCDC88A antibodies across different experimental platforms?

To ensure reliability and reproducibility when working with CCDC88A antibodies across different experimental platforms, researchers should implement comprehensive quality control measures:

• Antibody validation:

  • Verify specificity through knockout/knockdown controls

  • Test multiple antibodies targeting different epitopes

  • Confirm specificity with peptide competition assays

  • Document batch-to-batch variation with reference samples

• Experimental controls:

  • Include positive and negative tissue/cell controls

  • Use isotype controls to assess non-specific binding

  • Implement secondary-only controls to evaluate background

  • Consider recombinant CCDC88A as a standard reference

• Documentation practices:

  • Maintain detailed records of antibody source, lot number, and concentration

  • Document all experimental conditions, including buffer compositions

  • Record image acquisition parameters and analysis methods

  • Adhere to reporting guidelines such as ARRIVE for animal studies

• Reproducibility measures:

  • Perform technical and biological replicates

  • Blind analysis where possible to reduce bias

  • Use quantitative measures with appropriate statistical analysis

  • Consider inter-laboratory validation for critical findings

• Storage and handling verification:

  • Regularly test antibody performance after storage

  • Implement aliquoting to avoid freeze-thaw cycles

  • Monitor for degradation or contamination

  • Document storage conditions and duration